Skip to main content

Bladder Dysfunction in Older Adults: The Botulinum Toxin Option

Abstract

Bladder dysfunction, which involves inadequacies of urine storage or emptying, increases with age. Conventional medications may have insufficient efficacy for patients with refractory lower urinary tract symptoms, and their concomitant adverse events (AEs) may be intolerable for the older adult population. For decades, the botulinum toxin type A (BoNT-A) injection has been an option for managing urine frequency, urge incontinence, and voiding dysfunction in the general population refractory to conventional management. This review focuses on studies of BoNT-A application in the management of bladder dysfunction in older adult patients aged ≥ 65 years. In this target population, intravesical BoNT-A injections provide similar efficacy in idiopathic overactive bladder to that in younger adults. Good clinical response has also been demonstrated in older adult patients presenting with storage dysfunction and with various concomitant underlying neurological diseases. However, caution must be taken for the AEs that occur after intravesical BoNT-A injection, including increased post-void residual urine, acute urine retention, and urinary tract infection. Most evidence shows that age is not a major determinant of AEs after adjusting for other factors. In contrast to its application in storage dysfunction, evidence for voiding dysfunction in older adults is scarce. In general, BoNT-A may be a reasonable option for older adult patients with refractory storage dysfunction because of its promising clinical response without significant systemic AEs. Overall, clinicians should be aware of the balance between the therapeutic efficacy of BoNT-A and local AEs in vulnerable members of this population.

This is a preview of subscription content, access via your institution.

References

  1. Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230–7.

    PubMed  Article  Google Scholar 

  2. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14 (discussion 14–15).

    PubMed  Article  Google Scholar 

  3. Ko Y, Lin SJ, Salmon JW, Bron MS. The impact of urinary incontinence on quality of life of the elderly. Am J Manag Care. 2005;11(4 Suppl):S103–11.

    PubMed  Google Scholar 

  4. Pizzol D, Demurtas J, Celotto S, Maggi S, Smith L, Angiolelli G, et al. Urinary incontinence and quality of life: a systematic review and meta-analysis. Aging Clin Exp Res. 2021;33(1):25–35.

    PubMed  Article  Google Scholar 

  5. El-Gharib AK, Manzour AF, El-Mallah R, El Said SMS. Impact of urinary incontinence on physical performance and quality of life (QOL) amongst a group of elderly in Cairo. Int J Clin Pract. 2021;75(12): e14947.

    PubMed  Article  Google Scholar 

  6. Dugan E, Cohen SJ, Bland DR, Preisser JS, Davis CC, Suggs PK, et al. The association of depressive symptoms and urinary incontinence among older adults. J Am Geriatr Soc. 2000;48(4):413–6.

    CAS  PubMed  Article  Google Scholar 

  7. Chung A, Noguchi N, Chan L, Tse V. Voiding dysfunction in older men. Curr Opin Urol. 2016;26(2):177–83.

    PubMed  Article  Google Scholar 

  8. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9.

    CAS  PubMed  Article  Google Scholar 

  9. Malde S, Solomon E, Spilotros M, Mukhtar B, Pakzad M, Hamid R, et al. Female bladder outlet obstruction: common symptoms masking an uncommon cause. Lower Urinary Tract Symptoms. 2019;11(1):72–7.

    PubMed  Article  Google Scholar 

  10. Lin YH, Chiang BJ, Liao CH. Mechanism of action of botulinum toxin A in treatment of functional urological disorders. Toxins (Basel). 2020;12(2):129.

    CAS  PubMed Central  Article  Google Scholar 

  11. Jhang JF, Kuo HC. Novel applications of onabotulinumtoxina in lower urinary tract dysfunction. Toxins (Basel). 2018;10(7):260.

    PubMed Central  Article  CAS  Google Scholar 

  12. Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 2005;47(5):653–9.

    CAS  PubMed  Article  Google Scholar 

  13. Maria G, Cadeddu F, Brisinda D, Brandara F, Brisinda G. Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin. Curr Med Chem. 2005;12(3):247–65.

    CAS  PubMed  Article  Google Scholar 

  14. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers’ product summaries. J Clin Pharm Ther. 2007;32(4):387–402.

    CAS  PubMed  Article  Google Scholar 

  15. Andersson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology. 2003;62(5 Suppl 2):3–10.

    PubMed  Article  Google Scholar 

  16. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.

    CAS  PubMed  Article  Google Scholar 

  17. Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK Clinical Practice. Eur Urol. 2017;72(3):389–99.

    CAS  PubMed  Article  Google Scholar 

  18. Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term anticholinergic use and the aging brain. Alzheimer’s Dementia. 2013;9(4):377–85.

    PubMed  Article  Google Scholar 

  19. Kuo HC. OnabotulinumtoxinA treatment for overactive bladder in the elderly: practical points and future prospects. Drugs Aging. 2016;33(1):1–9.

    CAS  PubMed  Article  Google Scholar 

  20. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.

    PubMed  PubMed Central  Article  Google Scholar 

  21. Chancellor MB, Staskin DR, Kay GG, Sandage BW, Oefelein MG, Tsao JW. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012;29(4):259–73.

    CAS  PubMed  Article  Google Scholar 

  22. Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50(2):317–26.

    CAS  PubMed  Article  Google Scholar 

  23. Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64(1):74–81.

    CAS  PubMed  Article  Google Scholar 

  24. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc. 2002;50(5):799–807.

    PubMed  Article  Google Scholar 

  25. Staskin D, Kay G, Tannenbaum C, Goldman HB, Bhashi K, Ling J, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64(9):1294–300.

    CAS  PubMed  Article  Google Scholar 

  26. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease–systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337–52.

    CAS  PubMed  Article  Google Scholar 

  27. Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007;26(6):752–6.

    CAS  PubMed  Article  Google Scholar 

  28. Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320–7.

    CAS  PubMed  Article  Google Scholar 

  29. Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–32.

    CAS  PubMed  Article  Google Scholar 

  30. Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95.

    CAS  PubMed  Article  Google Scholar 

  31. Yamaguchi O, Marui E, Kakizaki H, Homma Y, Igawa Y, Takeda M, et al. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113(6):951–60.

    CAS  PubMed  Article  Google Scholar 

  32. Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.

    CAS  PubMed  Article  Google Scholar 

  33. Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015;34(7):685–92.

    CAS  PubMed  Article  Google Scholar 

  34. Wagg AS, Foley S, Peters J, Nazir J, Kool-Houweling L, Scrine L. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: retrospective analysis of a UK General Practice prescription database. Int J Clin Pract. 2017;71(10).

  35. Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020;77(2):211–20.

    CAS  PubMed  Article  Google Scholar 

  36. Herschorn S, Staskin D, Schermer CR, Kristy RM, Wagg A. Safety and tolerability results from the PILLAR study: a phase IV, double-blind, randomized, placebo-controlled study of mirabegron in patients ≥ 65 years with overactive bladder-wet. Drugs Aging. 2020;37(9):665–76.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. Shin DG, Kim HW, Yoon SJ, Song SH, Kim YH, Lee YG, et al. Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study. Neurourol Urodyn. 2019;38(1):295–304.

    CAS  PubMed  Article  Google Scholar 

  38. Yoshida M, Nozawa Y, Kato D, Tabuchi H, Kuroishi K. Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: analysis of a Japanese post-marketing study. Lower Urinary Tract Symptoms. 2019;11(1):30–8.

    CAS  PubMed  Article  Google Scholar 

  39. Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316–24.

    PubMed  Article  Google Scholar 

  40. Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR). J Urol. 2021;205(5):1421–9.

    PubMed  Article  Google Scholar 

  41. Varano S, Staskin D, Frankel J, Shortino D, Jankowich R, Mudd PN Jr. Efficacy and safety of once-daily vibegron for treatment of overactive bladder in patients aged ≥65 and ≥75 years: subpopulation analysis from the EMPOWUR randomized, international, phase III study. Drugs Aging. 2021;38(2):137–46.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. Kim DK, Lee JY, Jung JH, Kim JH, Hah YS, Hong CH, et al. Alpha-1 adrenergic receptor blockers for the treatment of lower urinary tract symptoms in women: a systematic review and meta-analysis. Int Neurourol J. 2019;23(1):56–68.

    PubMed  PubMed Central  Article  Google Scholar 

  43. Fusco F, Palmieri A, Ficarra V, Giannarini G, Novara G, Longo N, et al. α1-Blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol. 2016;69(6):1091–101.

    CAS  PubMed  Article  Google Scholar 

  44. Welk B, McArthur E, Fraser LA, Hayward J, Dixon S, Hwang YJ, et al. The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study. BMJ (Clinical Research Ed). 2015;351: h5398.

    PubMed Central  Google Scholar 

  45. Oelke M, Becher K, Castro-Diaz D, Chartier-Kastler E, Kirby M, Wagg A, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44(5):745–55.

    PubMed  PubMed Central  Article  Google Scholar 

  46. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2017;197(2s):S216–23.

    CAS  PubMed  Article  Google Scholar 

  47. Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56.

    CAS  PubMed  Article  Google Scholar 

  48. Liao CH, Chen SF, Kuo HC. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study. Neurourol Urodyn. 2016;35(6):717–23.

    CAS  PubMed  Article  Google Scholar 

  49. Mateu Arrom L, Mayordomo Ferrer O, Sabiote Rubio L, Gutierrez Ruiz C, Martínez Barea V, Palou Redorta J, et al. Treatment response and complications after intradetrusor onabotulinumtoxina injection in male patients with idiopathic overactive bladder syndrome. J Urol. 2020;203(2):392–7.

    PubMed  Article  Google Scholar 

  50. Yokoyama O, Honda M, Yamanishi T, Sekiguchi Y, Fujii K, Nakayama T, et al. OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis). Int J Urol. 2020;27(3):227–34.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217–22.

    PubMed  PubMed Central  Article  Google Scholar 

  52. White WM, Pickens RB, Doggweiler R, Klein FA. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol. 2008;180(6):2522–6.

    CAS  PubMed  Article  Google Scholar 

  53. Habashy D, Losco G, Tse V, Collins R, Chan L. Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes. BJU Int. 2015;116(Suppl 3):61–5.

    CAS  PubMed  Article  Google Scholar 

  54. Cohen BL, Caruso DJ, Kanagarajah P, Gousse AE. Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder. Adv Urol. 2009;2009: 328364.

    PubMed Central  Article  Google Scholar 

  55. Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013;189(5):1804–10.

    CAS  PubMed  Article  Google Scholar 

  56. Kim SH, Habashy D, Pathan S, Tse V, Collins R, Chan L. Eight-year experience with botulinum toxin type-A injections for the treatment of nonneurogenic overactive bladder: are repeated injections worthwhile? Int Neurourol J. 2016;20(1):40–6.

    PubMed  PubMed Central  Article  Google Scholar 

  57. Abrar M, Stroman L, Malde S, Solomon E, Sahai A. Predictors of poor response and adverse events following botulinum toxin-A for refractory idiopathic overactive bladder. Urology. 2020;135:32–7.

    PubMed  Article  Google Scholar 

  58. Andersson KE. Mechanisms of disease: central nervous system involvement in overactive bladder syndrome. Nat Clin Pract Urol. 2004;1(2):103–8.

    PubMed  Article  Google Scholar 

  59. Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol. 2009;182(4):1453–7.

    PubMed  Article  Google Scholar 

  60. Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011;186(3):960–4.

    CAS  PubMed  Article  Google Scholar 

  61. Anderson RU, Orenberg EK, Glowe P. OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson’s disease. Urology. 2014;83(1):22–7.

    PubMed  Article  Google Scholar 

  62. Kulaksizoglu H, Parman Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons’s disease. Parkinsonism Relat Disord. 2010;16(8):531–4.

    PubMed  Article  Google Scholar 

  63. Kuo HC. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology. 2006;67(2):232–6.

    PubMed  Article  Google Scholar 

  64. Jiang YH, Liao CH, Tang DL, Kuo HC. Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder. PLoS ONE. 2014;9(8): e105989.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  65. Wang CC, Jiang YH, Kuo HC. The pharmacological mechanism of diabetes mellitus-associated overactive bladder and its treatment with botulinum toxin A. Toxins. 2020;12(3):186.

    CAS  PubMed Central  Article  Google Scholar 

  66. Golbidi S, Laher I. Bladder dysfunction in diabetes mellitus. Front Pharmacol. 2010;1:136.

    PubMed  PubMed Central  Article  Google Scholar 

  67. Wang CC, Liao CH, Kuo HC. Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity. Neurourol Urodyn. 2014;33(8):1235–9.

    CAS  PubMed  Article  Google Scholar 

  68. Kao YL, Huang KH, Kuo HC, Ou YC. The therapeutic effects and pathophysiology of botulinum toxin a on voiding dysfunction due to urethral sphincter dysfunction. Toxins. 2019;11(12):728.

    CAS  PubMed Central  Article  Google Scholar 

  69. Ou YC, Huang KH, Jan HC, Kuo HC, Kao YL, Tsai KJ. Therapeutic efficacy of urethral sphincteric botulinum toxin injections for female sphincter dysfunctions and a search for predictive factors. Toxins (Basel). 2021;13(6):398.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. Lin AT, Yang AH, Chen KK. Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol. 2007;52(2):582–9.

    CAS  PubMed  Article  Google Scholar 

  71. Chuang YC, Huang CC, Kang HY, Chiang PH, Demiguel F, Yoshimura N, et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol. 2006;175(3 Pt 1):1158–63.

    CAS  PubMed  Article  Google Scholar 

  72. Chiang BJ, Kuo HC, Liao CH. Can botulinum toxin A still have a role in treatment of lower urinary tract symptoms/benign prostatic hyperplasia through inhibition of chronic prostatic inflammation? Toxins. 2019;11(9):547.

    CAS  PubMed Central  Article  Google Scholar 

  73. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003;62(2):259–64 (discussion 64–65).

    PubMed  Article  Google Scholar 

  74. Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT, et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol. 2011;186(3):965–70.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  75. Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology. 2005;66(4):775–9.

    PubMed  Article  Google Scholar 

  76. Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int. 2006;98(5):1033–7 (discussion 337).

    CAS  PubMed  Article  Google Scholar 

  77. Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P, et al. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol. 2008;53(1):153–9.

    CAS  PubMed  Article  Google Scholar 

  78. Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Oliveira R, et al. Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol. 2009;9:9.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  79. Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology. 2009;73(1):90–4.

    PubMed  Article  Google Scholar 

  80. Kuo HC. Prostate botulinum A toxin injection: an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology. 2005;65(4):670–4.

    PubMed  Article  Google Scholar 

  81. Hamidi Madani A, Enshaei A, Heidarzadeh A, Mokhtari G, Farzan A, Mohiti Asli M, et al. Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates. World J Urol. 2013;31(1):235–9.

    CAS  PubMed  Article  Google Scholar 

  82. Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2013;63(3):496–503.

    CAS  PubMed  Article  Google Scholar 

  83. McVary KT, Roehrborn CG, Chartier-Kastler E, Efros M, Bugarin D, Chen R, et al. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2014;192(1):150–6.

    CAS  PubMed  Article  Google Scholar 

  84. Hsu YC, Wang HJ, Chuang YC. Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia-a spotlight in reality. Toxins. 2016;8(5):126.

    PubMed Central  Article  CAS  Google Scholar 

  85. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. Management of Non-neurogenic Male LUTS. 2021. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/. Accessed 12 Feb 2022.

  86. Miotla P, Cartwright R, Skorupska K, Bogusiewicz M, Markut-Miotla E, Futyma K, et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk? Int Urogynecol J. 2017;28(6):845–50.

    PubMed  Article  Google Scholar 

  87. Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol. 2010;58(6):919–26.

    CAS  PubMed  Article  Google Scholar 

  88. Nitti V, Drake M, Everaert K, Rovner E, Dmochowski R, Ginsberg D, et al. Low incidence of clean intermittent catheterisation with onabotulinumtoxinA in diverse age groups of overactive bladder patients with corresponding improvements in urinary symptoms, treatment response, and quality of life. Neurourology and Urodynamics. Hoboken: Wiley; 2017. p. S300-S1.

  89. Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22.

    CAS  PubMed  Article  Google Scholar 

  90. Stephany HA, Strand DW, Ching CB, Tanaka ST, Milne GL, Cajaiba MM, et al. Chronic cyclic bladder over distention up-regulates hypoxia dependent pathways. J Urol. 2013;190(4 Suppl):1603–9.

    PubMed  PubMed Central  Article  Google Scholar 

  91. Jiang YH, Ong HL, Kuo HC. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome: a real-life practice of 290 cases in a single center. Neurourol Urodyn. 2017;36(1):142–7.

    CAS  PubMed  Article  Google Scholar 

  92. Wiedemann A, Haider S, Heppner HJ. Does intravesical application of botulinum toxin lead to systemic muscle weakness? An approach to an uro-geriatric problem [in German]. Aktuelle Urol. 2020;51(1):48–52.

    PubMed  Article  Google Scholar 

  93. Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol. 2017;71(3):353–65.

    PubMed  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hann-Chorng Kuo.

Ethics declarations

Conflict of interest

Yao-Lin Kao, Yin-Chien Ou, and Hann-Chorng Kuo declare no conflicts of interest.

Funding

The work was supported by grants from the National Cheng Kung University Hospital (NCKUH-11103038).

Ethics approval

Not applicable.

Informed consent

Not applicable.

Consent for publication

Not applicable.

Data availability

Not applicable.

Code availability

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Author contributions

H-CK: Conceptualization; project administration, supervision, and writing–review and editing. Y-LK: Methodology, resources, and writing–original draft. Y-CO: Visualization, writing–original draft. All authors have read and agreed to the published version of this manuscript.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kao, YL., Ou, YC. & Kuo, HC. Bladder Dysfunction in Older Adults: The Botulinum Toxin Option. Drugs Aging 39, 401–416 (2022). https://doi.org/10.1007/s40266-022-00950-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-022-00950-1